Voyager Therapeutics, Inc. logo VYGR - Voyager Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 17
HOLD 4
SELL 0
STRONG
SELL 0
| PRICE TARGET: $14.40 DETAILS
HIGH: $18.00
LOW: $8.00
MEDIAN: $18.00
CONSENSUS: $14.40
UPSIDE: 278.95%

Stock News

Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026

Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026

- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager's continued innovation in gene therapy - LEXINGTON, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today presented three-month good laboratory practice (GLP) toxicology data for VY1706, the Company's investigational tau silencing gene therapy for Alzheimer's disease (AD), in a late-breaking presentation at the American Society of Gene & Cell Therapy's (ASGCT) 2026 Annual Meeting in Boston, May 11-15, 2026.

May 13, 2026 02:01 AM • globenewswire.com
Voyager Reports First Quarter 2026 Financial and Operating Results

Voyager Reports First Quarter 2026 Financial and Operating Results

- VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 - - Multiple presentations at ASGCT 2026, including late breaker on VY1706 3-month GLP tox data - - Ended Q1 2026 with cash position of $172 million, runway into 2028 - LEXINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported first quarter 2026 financial and operating results.

May 07, 2026 12:01 PM • globenewswire.com
Reviewing Longeveron (NASDAQ:LGVN) & Voyager Therapeutics (NASDAQ:VYGR)

Reviewing Longeveron (NASDAQ:LGVN) & Voyager Therapeutics (NASDAQ:VYGR)

Longeveron (NASDAQ: LGVN - Get Free Report) and Voyager Therapeutics (NASDAQ: VYGR - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability. Risk and Volatility Longeveron has a beta of

Apr 13, 2026 09:09 PM • defenseworld.net
Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026

Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026

Voyager Therapeutics maintains a "Strong Buy" rating as it approaches a pivotal 2026 catalyst with tau PET imaging data from its phase 1b study in Alzheimer's disease. Company's anti-tau monoclonal antibody VY7523 demonstrated an excellent safety and PK profile in phase 1 SAD, enabling advancement to phase 1b MAD in early AD patients. Company's robust cash position, projected to fund operations into 2028, is further supported by potential $2.4B in milestone payments and ongoing collaborations.

Apr 12, 2026 11:28 PM • seekingalpha.com
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 -  - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 - - Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile - - Ended 2025 with cash position of $202 million, expected to maintain runway into 2028 - LEXINGTON, Mass.

Mar 09, 2026 12:01 PM • globenewswire.com
Voyager Therapeutics Touts Tau, Gene Therapy and NeuroShuttle Roadmap, Sees Cash Runway Into 2028

Voyager Therapeutics Touts Tau, Gene Therapy and NeuroShuttle Roadmap, Sees Cash Runway Into 2028

Voyager Therapeutics (NASDAQ: VYGR) outlined what CEO Al Sandrock described as three "pillars of value" for the year ahead during a discussion at Oppenheimer's 36th Annual Life Science Conference, pointing to advancing two tau-directed programs, initiating two gene therapy clinical entries using its blood-brain barrier-penetrant capsids, and building out its emerging NeuroShuttle platform for brain delivery

Mar 02, 2026 12:05 AM • defenseworld.net
Contrasting Voyager Therapeutics (NASDAQ:VYGR) and Alvotech (NASDAQ:ALVO)

Contrasting Voyager Therapeutics (NASDAQ:VYGR) and Alvotech (NASDAQ:ALVO)

Alvotech (NASDAQ: ALVO - Get Free Report) and Voyager Therapeutics (NASDAQ: VYGR - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability. Insider and Institutional Ownership 48.0% of Voyager Therapeutics

Jan 17, 2026 09:24 PM • defenseworld.net

Price Targets